REG - Kanabo Group PLC - Result of AGM

KanaboAnnouncement

30/06/2023 14:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230630:nRSd6041Ea&default-theme=true

RNS Number : 6041E  Kanabo Group PLC  30 June 2023

30 June 2023

Kanabo Group Plc

("Kanabo" or the "Company")

 

Result of AGM

 

Kanabo Group Plc (LSE:KNB), the patient focused healthcare technology and
medicinal cannabis company, announces that at the Annual General Meeting
("AGM") held earlier today thirteen resolutions were duly passed. The numbers
of votes for each resolution are presented below:

 

 Resolution (No. as noted on proxy form)  Total For (i)          Total Against          Withheld (ii)
                                          No. of votes  % of     No. of votes  % of     No. of votes

                                                        vote                   vote
 Resolution 1                             231,148,817   99.93%   162,363       0.07%    74,145

 Resolution 2                             230,958,946   99.90%   230,317       0.10%    196,062

 Resolution 3                             161,657,876   99.88%   197,595       0.12%    69,529,854

 Resolution 4                             223,079,901   96.45%   8,201,867     3.55%    103,557

 Resolution 5                             223,081,901   96.46%   8,198,729     3.54%    104,695

 Resolution 6                             223,091,027   96.46%   8,189,603     3.54%    104,695

 Resolution 7                             231,103,813   99.91%   199,779       0.09%    81,733

 Resolution 8                             223,053,034   96.44%   8,245,185     3.56%    87,106

 Resolution 9 (iii)                       153,592,369   66.41%   77,697,479    33.59%   95,477

 Resolution 10                            231,033,085   99.86%   313,000       0.14%    39,240

 Resolution 11 (iii)                      223,042,578   96.41%   8,303,507     3.59%    39,240

 Resolution 12                            222,934,014   96.41%   8,304,818     3.59%    146,493

 Resolution 13                            231,033,617   99.89%   254,406       0.11%    97,302

 Resolution 14 (iii)                      223,042,110   96.41%   8,302,150     3.59%    41,065

 

(i)            The "For" Proxy vote includes those giving the Chair
of the AGM discretion

(ii)           A vote "Withheld" is not a vote in law and is not
included in the proxy votes "For" or "Against" the resolution

(iii)          Special resolution

 

The full text of the resolutions can be found in the Notice of Annual General
Meeting, which is available on the Company's website at:
https://www.kanabogroup.com/investors/
(https://www.kanabogroup.com/investors/)

 

 For further information, please visit http://www.kanabogroup.com/
(http://www.kanabogroup.com/)  or contact the following:

 

Enquiries:

 

 Kanabo Group plc                                                  via Vigo Consulting

 Avihu Tamir, Chief Executive Officer                              +44 (0)20 7390 0230

 Assaf Vardimon, Chief Financial Officer

Ian Mattioli, Non-Executive Chair of the Board

 Peterhouse Capital Ltd (Financial Adviser and Broker)             +44 (0)20 7469 0930

 Eran Zucker/ Lucy Williams / Charles Goodfellow

 Vigo Consulting (Financial Public Relations/Investor Relations)    +44 (0)20 7390 0230

 Jeremy Garcia / Fiona Hetherington / Verity Snow

 kanabo@vigoconsulting.com

 

 

About Kanabo Group Plc

Kanabo Group Plc (LSE:KNB) is a healthtech company committed to
revolutionising patient care through its innovative technology platform and
disruptive product offerings. Since its inception in 2017, Kanabo has been
focused on researching, developing, and commercialising regulated medicinal
cannabis-derived formulations and therapeutic inhalation devices.

 

Kanabo's NHS-approved online telehealth platform, The GP Service, provides
patients with video consultations, online prescriptions, and primary care
services. The Company is a leader in its field, focusing on improving patient
outcomes and providing more accessible healthcare experiences.

 

In March 2023, Kanabo successfully launched its Pain Clinic, Treat It, under
the expert guidance of its technological and product expertise. Treat It
initially focuses on chronic pain management using plant-based medicine and
treatments that are currently unavailable through traditional channels.

 

At Kanabo Group Plc, we are dedicated to providing patients with the highest
quality medical treatments and more accessible healthcare experiences.

 

Visit www.kanabogroup.com (http://www.kanabogroup.com/)  for more
information.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGEADKEDDFDEFA